599 related articles for article (PubMed ID: 17434581)
21. Versatility of biodegradable poly(D,L-lactic-co-glycolic acid) microspheres for plasmid DNA delivery.
Díez S; Tros de Ilarduya C
Eur J Pharm Biopharm; 2006 Jun; 63(2):188-97. PubMed ID: 16697172
[TBL] [Abstract][Full Text] [Related]
22. Using TEM to couple transient protein distribution and release for PLGA microparticles for potential use as vaccine delivery vehicles.
Zhao A; Rodgers VG
J Control Release; 2006 Jun; 113(1):15-22. PubMed ID: 16707186
[TBL] [Abstract][Full Text] [Related]
23. Development of a novel morphological paclitaxel-loaded PLGA microspheres for effective cancer therapy: in vitro and in vivo evaluations.
Zhang Z; Wang X; Li B; Hou Y; Yang J; Yi L
Drug Deliv; 2018 Nov; 25(1):166-177. PubMed ID: 29299936
[TBL] [Abstract][Full Text] [Related]
24. Gelatin/chitosan/hyaluronan scaffold integrated with PLGA microspheres for cartilage tissue engineering.
Tan H; Wu J; Lao L; Gao C
Acta Biomater; 2009 Jan; 5(1):328-37. PubMed ID: 18723417
[TBL] [Abstract][Full Text] [Related]
25. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives.
Mundargi RC; Babu VR; Rangaswamy V; Patel P; Aminabhavi TM
J Control Release; 2008 Feb; 125(3):193-209. PubMed ID: 18083265
[TBL] [Abstract][Full Text] [Related]
26. Effects of lung surfactants on rifampicin release rate from monodisperse rifampicin-loaded PLGA microspheres.
Tomoda K; Makino K
Colloids Surf B Biointerfaces; 2007 Mar; 55(1):115-24. PubMed ID: 17197161
[TBL] [Abstract][Full Text] [Related]
27. Poly(vinyl alcohol)-graft-poly(lactide-co-glycolide) nanoparticles for local delivery of paclitaxel for restenosis treatment.
Westedt U; Kalinowski M; Wittmar M; Merdan T; Unger F; Fuchs J; Schäller S; Bakowsky U; Kissel T
J Control Release; 2007 May; 119(1):41-51. PubMed ID: 17346845
[TBL] [Abstract][Full Text] [Related]
28. Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum.
Kohane DS; Tse JY; Yeo Y; Padera R; Shubina M; Langer R
J Biomed Mater Res A; 2006 May; 77(2):351-61. PubMed ID: 16425240
[TBL] [Abstract][Full Text] [Related]
29. Protein complexed with chondroitin sulfate in poly(lactide-co-glycolide) microspheres.
Lee ES; Park KH; Kang D; Park IS; Min HY; Lee DH; Kim S; Kim JH; Na K
Biomaterials; 2007 Jun; 28(17):2754-62. PubMed ID: 17337049
[TBL] [Abstract][Full Text] [Related]
30. Poly(D,L lactic-co-glycolic acid) microspheres as biodegradable microcarriers for pluripotent stem cells.
Newman KD; McBurney MW
Biomaterials; 2004 Nov; 25(26):5763-71. PubMed ID: 15147822
[TBL] [Abstract][Full Text] [Related]
31. Effect of polyethylene glycol on preparation of rifampicin-loaded PLGA microspheres with membrane emulsification technique.
Ito F; Fujimori H; Honnami H; Kawakami H; Kanamura K; Makino K
Colloids Surf B Biointerfaces; 2008 Oct; 66(1):65-70. PubMed ID: 18585903
[TBL] [Abstract][Full Text] [Related]
32. Preparation and characterization of electrospun PLGA/gelatin nanofibers as a potential drug delivery system.
Meng ZX; Xu XX; Zheng W; Zhou HM; Li L; Zheng YF; Lou X
Colloids Surf B Biointerfaces; 2011 May; 84(1):97-102. PubMed ID: 21227661
[TBL] [Abstract][Full Text] [Related]
33. Biodegradable PLGA microcarriers for injectable delivery of chondrocytes: effect of surface modification on cell attachment and function.
Chun KW; Yoo HS; Yoon JJ; Park TG
Biotechnol Prog; 2004; 20(6):1797-801. PubMed ID: 15575714
[TBL] [Abstract][Full Text] [Related]
34. Characterization of biodegradable drug delivery vehicles with the adhesive properties of leukocytes II: effect of degradation on targeting activity.
Eniola AO; Hammer DA
Biomaterials; 2005 Feb; 26(6):661-70. PubMed ID: 15282144
[TBL] [Abstract][Full Text] [Related]
35. PLGA-based drug delivery systems: importance of the type of drug and device geometry.
Klose D; Siepmann F; Elkharraz K; Siepmann J
Int J Pharm; 2008 Apr; 354(1-2):95-103. PubMed ID: 18055140
[TBL] [Abstract][Full Text] [Related]
36. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation.
Danhier F; Lecouturier N; Vroman B; Jérôme C; Marchand-Brynaert J; Feron O; Préat V
J Control Release; 2009 Jan; 133(1):11-7. PubMed ID: 18950666
[TBL] [Abstract][Full Text] [Related]
37. In vitro study of anticancer drug doxorubicin in PLGA-based microparticles.
Lin R; Shi Ng L; Wang CH
Biomaterials; 2005 Jul; 26(21):4476-85. PubMed ID: 15701377
[TBL] [Abstract][Full Text] [Related]
38. Facile control of porous structures of polymer microspheres using an osmotic agent for pulmonary delivery.
Lee J; Oh YJ; Lee SK; Lee KY
J Control Release; 2010 Aug; 146(1):61-7. PubMed ID: 20553775
[TBL] [Abstract][Full Text] [Related]
39. How porosity and size affect the drug release mechanisms from PLGA-based microparticles.
Klose D; Siepmann F; Elkharraz K; Krenzlin S; Siepmann J
Int J Pharm; 2006 May; 314(2):198-206. PubMed ID: 16504431
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic effect of in vivo sustained estradiol release from poly (lactide-co-glycolide) microspheres on bone mineral density of osteoporosis rats.
Otsuka M; Uenodan H; Matsuda Y; Mogi T; Ohshima H; Makino K
Biomed Mater Eng; 2002; 12(2):157-67. PubMed ID: 12122239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
